Service Médecine Nucléaire
Caen, 14000, France
NCT Number: NCT02510872
Early detection of viable residual tumor or early neoplastic recurrence represents a real challenge in monitoring patients treated with concomitant chemoradiotherapy squamous cell carcinoma of the upper aerodigestive tract.
The locoregional recurrence rate is indeed high (up 40%) over the first two years of this therapeutic method.
The conventional imaging methods such as CT and MRI appear limited in terms of sensitivity because of the many post-treatment changes are fibrosis, tissue edema and the tissue distortion.
PET-CT 18F-FDG proves to be a non-invasive, reliable for the detection of residual tumor and metastasis, even in the absence of clinical signs.
To date, the acquired CT examination in the same time and in the same position that PET is performed without iodinated contrast injection, used for anatomical identification and attenuation correction of PET fused images. The patient usually has a second CT imaging, centered on the neck with contrast injection iodized within the radiology department.
To date, no team has yet studied the interest of the PET-CT 18F-FDG coupled with a CT scan with contrast injection iodized in the diagnosis of early recurrence in head and neck malignancies while interest of the contrast agent injection has been demonstrated in ovarian neoplastic recurrence research, pancreatic and colon.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Caen, 14000, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: baseline
Final classification review (Benin, malignant or suspicious)
University Hospital, Caen
Other
Acronym: TEPVAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02296684
Cancer of Head and Neck, Carcinoma
Boston, Massachusetts, United States
View Trial DetailsNCT04290546
Carcinoma, Carcinoma, Squamous Cell
Boston, Massachusetts, United States
View Trial DetailsNCT04609566
Bronchial Neoplasms, Carcinoma
Tucson, Arizona, United States
View Trial DetailsNCT04881045
Adnexal Diseases, Bronchial Neoplasms
Phoenix, Arizona, United States
View Trial Details